Research & Innovation
Welcome to Burley Labs, where cutting-edge science meets collaborative exploration
Advancing the development of next-generation therapeutics
Our Key Research Areas
Bioconjugate
Design
We are developing a new class of bioconjugates to deliver drug payloads to the cell target of interest.
Development of synthetic transcription factors to modulate the expression of target genes.
The primary research group’s focus areas are exploring the molecular basis of gene expression, and developing next generation therapeutics to correct for aberrant gene expression present in many diseases. We also develop new bioconjugation chemistries to deliver therapeutic payloads to the desired cell or tissue of interest.
The research team is dedicated to exploring gene expression, developing new drug delivery platform, and the identification of next generation therapeutics. We believe in the power of collaboration to drive impactful discoveries with our collaborators and industrial partners, and to support the academic growth of our team members.
Publications
Chemical biology research group addressing molecular mechanisms of biological processes relating to human disease.
119.
Split-APEX implicates splicing factor SRSF1 and splicing helicases in ribosomal biogenesis
118.
Antibody-drug conjugates as multimodal therapies against hard-to-treat cancers
117.
Long-Range Allosteric Modulation of DNA Duplex Dynamics Induced by Pyrrole-Imidazole Polyamide Binding
115.
Preparation of nucleoside analogues: opportunities for innovation at the interface of synthetic chemistry and biocatalysis
